Randomized, open-label, phase three study comparing flutamide and abiraterone in patients with advanced prostate cancer after failure of first combined androgen blockade therapy.
Not Applicable
Recruiting
- Conditions
- prostate cancer
- Registration Number
- JPRN-UMIN000016617
- Lead Sponsor
- agoya City University Graduate School of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have other active cancer, infection diseases or glaucome are excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Biochemical-free Survival rate
- Secondary Outcome Measures
Name Time Method